Abstract

REVIEW ON IMEGLIMIN A NOVEL THERAPEUTIC AGENT FOR TYPE 2 DIABETES

Avi Shah, Pavan Patel, Faizan Khorajiya*, Jignesh Parmar, Khushbu Patel and Dr. C. N. Patel

.

Abstract

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favorable safety and tolerability profile, including the lack of severe hypoglycemia. Imeglimin is unique and different in action compared to other hypoglycemic drugs. meglimin's mechanism of action involves dual effects: (1) amplification of glucose‐stimulated insulin secretion (GSIS) and preservation of β‐cell mass; and (2) enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle. Imeglimin has been shown to have a beneficial effect on 3 key pathogenetic elements of Type 2 diabetes mellitus, i.e., 1. increased gluconeogenesis, 2. inadequate glucose-induced insulin secretion by beta cells, and 3. peripheral insulin resistance. Subjects receiving Imeglimin at 1000- and 1500-mg doses twice daily also achieved significantly greater reductions in fasting plasma glucose (FPG) levels at week 24 compared to the placebo group. This review can be helpful for further study of Imeglimin hydrochloride.

Keywords: Imeglimin, Type 2 diabetes, Hypoglycaemic agent, Glimins, Insuline increasing agent.